Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Uniqure NV(QURE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for QURE
11/13/2026: QURE (1-star) is currently NOT-A-BUY. Pass it for now.
Uniqure NV is a biopharmaceutical company focused on developing one-time gene therapies for rare genetic disorders, most notably Hemophilia B. Its primary strength lies in its proprietary AAV platform and in-house manufacturing, which distinguish it as a specialized developer in the genomic medicine space. The main investment story centers on its potential to deliver long-term value through pipeline assets like AMT-130 for Huntington's disease. However, investors face substantial risks, including a high cash burn, clinical data sensitivity, and complex regulatory paths. Uniqure may suit growth-oriented investors with high risk tolerance who are looking for exposure to potential medical breakthroughs in rare diseases while closely monitoring regulatory outcomes.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | As a high-risk biotech with transformative potential, it fits the profile of investors seeking long-term capital appreciation from breakthrough medical tech. |
| Momentum investor | Mixed fit | Momentum is highly conditional on news cycles; it can see massive volatility around clinical data releases. |
| Value investor | Weak fit | Lacks current earnings, dividends, or consistent cash flows, making it an unattractive target for traditional value strategies. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on aggressive R&D reinvestment. |
| Low-risk investor | Weak fit | The high volatility and clinical-stage nature of the business make it unsuitable for capital preservation goals. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are susceptible to extreme price swings based on clinical trial results and FDA decisions. |
| Valuation risk | High | Valuations are based on long-term drug success projections, which are inherently uncertain. |
| Competition risk (gene therapy space) | Medium / high | Numerous well-funded competitors are also pursuing similar gene-based platforms. |
| Business quality | Medium | Uniqure is a pioneer with manufacturing expertise, but business sustainability depends entirely on R&D success. |
| Dividend income | Low / none | There is no income component for shareholders. |
| Execution risk | High | The complexity of manufacturing and the high bar for regulatory approval pose persistent risks. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.67B USD | Price to earnings Ratio - | 1Y Target Price 59.44 |
Price to earnings Ratio - | 1Y Target Price 59.44 | ||
Volume (30-day avg) 2.0M shares | Beta 1.13 | 52 Weeks Range 8.73 - 51.72 | Updated Date 11/14/2026 |
52 Weeks Range 8.73 - 51.72 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.39 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -32.19% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| License and Milestone Revenue | Payments received from partners like CSL Behring for commercialized assets like HEMGENIX. | Revenue is not currently driven by broad retail product sales but by specialized pharmaceutical partnerships. |
| Geography (US/Europe) | Operations split between US and Netherlands centers for R&D and production. | The company is global in scope, but its financial performance is currently dependent on high-value drug approvals in US and EU markets. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 27.93 | Enterprise Value 1.12B | Price to Sales(TTM) 82.81 |
Enterprise Value 1.12B | Price to Sales(TTM) 82.81 | ||
Enterprise Value to Revenue 55.59 | Enterprise Value to EBITDA 1.4 | Shares Outstanding 70.14M | Shares Floating 58.29M |
Shares Outstanding 70.14M | Shares Floating 58.29M | ||
Percent Insiders 1.26 | Percent Institutions 95.87 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.